Trial Profile
A pilot study of oral dasatinib in subjects with MDS [myelodysplastic syndromes] and excess marrow blasts.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 03 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2012 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 02 May 2012 Planned End Date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.